t
| Date | 23 Nov 2022 |
| Time | 07:00:08 |
| Category | Corporate updates |
| ID | 3312H |
|
For immediate release |
23 November 2022 |
ALLIANCE PHARMA
("Alliance", "Company" or the "Group")
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that Peter Butterfield, Chief Executive Officer, is taking time away from the business for personal reasons. He is expected to return during January 2023.
Andrew Franklin, Chief Financial Officer, has assumed Peter's CEO responsibilities, in line with the Group's established resilience plans, with support from the Head of Finance and the wider leadership team.
For further information:
|
Alliance Pharma plc |
+ 44 (0)1249 466966 |
|
Cora McCallum, Head of Investor Relations & Corporate Communications |
+ 44 (0)1249 705168 |
|
|
|
|
|
|
|
Buchanan |
+ 44 (0)20 7466 5000 |
|
Mark Court / Hannah Ratcliff |
|
|
|
|
|
|
|
|
Numis Securities Limited |
+ 44 (0)20 7260 1000 |
|
Nominated Adviser: Freddie Barnfield / Duncan Monteith |
|
|
Corporate Broking: James Black |
|
|
|
|
|
Investec Bank plc |
+ 44 (0)20 7597 5970 |
|
Corporate Finance: Daniel Adams |
|
|
Corporate Broking: Patrick Robb |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com